{
    "balance": {
        "data": [
            "CONSOLIDATED BALANCE SHEETS\tDollars in Millions\t(UNAUDITED)\tASSETS\tMarch 31,\t2021\tDecember 31,\t2020\tCurrent Assets:\tCash and cash equivalents\t$\t10,982\t$\t14,546\tMarketable debt securities\t1,948\t1,285\tReceivables\t8,660\t8,501\tInventories\t1,953\t2,074\tOther current assets\t3,568\t3,786\tTotal Current Assets\t27,111\t30,192\tProperty, plant and equipment\t5,763\t5,886\tGoodwill\t20,524\t20,547\tOther intangible assets\t50,819\t53,243\tDeferred income taxes\t793\t1,161\tMarketable debt securities\t288\t433\tOther non-current assets\t7,137\t7,019\tTotal Assets\t$\t112,435\t$\t118,481\tLIABILITIES\tCurrent Liabilities:\tShort-term debt obligations\t$\t1,777\t$\t2,340\tAccounts payable\t2,972\t2,713\tOther current liabilities\t12,581\t14,027\tTotal Current Liabilities\t17,330\t19,080\tDeferred income taxes\t5,235\t5,407\tLong-term debt\t44,505\t48,336\tOther non-current liabilities\t7,692\t7,776\tTotal Liabilities\t74,762\t80,599\tCommitments and contingencies\tEQUITY\tBristol-Myers Squibb Company Shareholders  Equity:\tPreferred stock\t \t \tCommon stock\t292\t292\tCapital in excess of par value of stock\t43,852\t44,325\tAccumulated other comprehensive loss\t(\t1,544\t)\t(\t1,839\t)\tRetained earnings\t22,204\t21,281\tLess cost of treasury stock\t(\t27,199\t)\t(\t26,237\t)\tTotal Bristol-Myers Squibb Company Shareholders  Equity\t37,605\t37,822\tNoncontrolling interest\t68\t60\tTotal Equity\t37,673\t37,882\tTotal Liabilities and Equity\t$\t112,435\t$\t118,481\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBRISTOL-MYERS SQUIBB COMPANY\tCONSOLIDATED STATEMENTS OF CASH FLOWS\tDollars in Millions\t(UNAUDITED)\tThree Months Ended March 31,\t2021\t2020\tCash Flows From Operating Activities:\tNet earnings/(loss)\t$\t2,029\t$\t(\t766\t)\tAdjustments to reconcile net earnings/(loss) to net cash provided by operating activities:\tDepreciation and amortization, net\t2,668\t2,477\tDeferred income taxes\t68\t(\t53\t)\tStock-based compensation\t151\t210\tImpairment charges\t339\t53\tPension settlements and amortization\t11\t11\tDivestiture gains and royalties\t(\t135\t)\t(\t173\t)\tAsset acquisition charges\t5\t46\tEquity investment (gains)/losses\t(\t601\t)\t338\tContingent consideration fair value adjustments\t(\t510\t)\t556\tOther adjustments\t233\t(\t41\t)\tChanges in operating assets and liabilities:\tReceivables\t67\t(\t743\t)\tInventories\t106\t1,448\tAccounts payable\t303\t703\tIncome taxes payable\t227\t229\tOther\t(\t1,137\t)\t(\t358\t)\tNet Cash Provided by Operating Activities\t3,824\t3,937\tCash Flows From Investing Activities:\tSale and maturities of marketable debt securities\t782\t1,394\tPurchase of marketable debt securities\t(\t1,302\t)\t(\t735\t)\tCapital expenditures\t(\t173\t)\t(\t186\t)\tDivestiture and other proceeds\t585\t205\tAcquisition and other payments, net of cash acquired\t(\t35\t)\t(\t68\t)\tNet Cash (Used in)/Provided by Investing Activities\t(\t143\t)\t610\tCash Flows From Financing Activities:\tShort-term debt obligations, net\t(\t62\t)\t26\tRepayment of long-term debt\t(\t4,522\t)\t \tRepurchase of common stock\t(\t1,775\t)\t(\t81\t)\tDividends\t(\t1,108\t)\t(\t1,017\t)\tOther\t172\t18\tNet Cash Used in Financing Activities\t(\t7,2"
        ],
        "timestamp": "2025-01-21_09-31-15"
    }
}